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Abstract
The roles of PKC in iNOS induction by IFN-Q have been shown in some cell types. The effect of a PKC activator, phorbol
ester, in iNOS induction is thought to be due to multiple mechanisms, and it is necessary to examine the involvement of
phorbol ester on IFN-Q-induced iNOS in detail. In the present study, we investigated the mechanisms of phorbol ester on
IFN-Q-induced iNOS in RAW 264.7 cells. PMA synergistically increased iNOS activity, protein and mRNA levels in IFN-Q-
treated RAW 264.7 cells. PMA together with IFN-Q increased iNOS mRNA without affecting the iNOS mRNA degradation,
suggesting that the synergistic effect of PMA on IFN-Q-induced iNOS mRNA production may depend on the elevation of the
transcription rate rather than a prolongation of mRNA stability. The DNA binding proteins that are involved in the
regulation of iNOS expression are mainly NF-UB and IRF-1. IRF-1 transcriptionally regulates many IFN-inducible genes
such as iNOS whose promoter contains an IRF-1 binding site. PMA might modulate iNOS induction as a cosignal with IFN-
Q in RAW 264.7 cells because the synergistic effect of PMA was mediated through IRF-1, rather than NF-UB. Ro 31-8220, a
PKC inhibitor, decreased iNOS activity, protein, mRNA levels and IRF-1 activity, indicating that the effect of PMA on
iNOS induction might occur via the PKC pathway. It is evidence that PKC plays an important role in IRF-1 activation and
that phorbol ester has a synergistic effect on iNOS induction through IRF-1 activation in IFN-Q-treated RAW 264.7 cells.
The synergistic effect of PMA on IFN-Q-induced IRF-1 binding activity was observed in macrophage cell line J774 cells as
well as RAW 264.7 cells, but not in thioglycollate-elicited peritoneal macrophages. ß 2000 Elsevier Science B.V. All rights
reserved.
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1. Introduction
Nitric oxide (NO) is a short-lived free radical and
an important signaling molecule that has been dem-
onstrated to play a role in diverse physiological pro-
cesses such as vasodilation [1^3], neurotransmission
[4,5], and cytotoxicity [6^9]. NO is produced by nitric
oxide synthases (NOS) which oxidize the guanidino
nitrogen of L-arginine, resulting in equal amounts of
L-citrulline and NO [10,11]. At least, three isoforms
of NOS have been identi¢ed: endothelial NOS
(eNOS), neural NOS (nNOS) and macrophage
NOS (mNOS), each of which is the product of a
distinct gene [12]. Endothelial and neural NOS are
constitutively expressed in Ca2/calmodulin-depen-
dent enzymes, whereas macrophage NOS, the so-
called cytokine-inducible NOS (iNOS), is a Ca2/cal-
modulin-independent isoform [6,10,13] that is ex-
pressed when exposed to many cytokines such as
interferon-Q (IFN-Q) and/or bacterial cell wall prod-
ucts such as lipopolysaccharide (LPS) in di¡erent cell
types [14^16].
The promoter region of the iNOS gene has been
characterized in di¡erent species, including human
and mouse [17,18]. Sequence analysis of the pro-
moter revealed the presence of consensus motifs for
binding of transcription factors such as NF-UB and
interferon regulatory factor-1 (IRF-1) [18^21]. In
macrophages, the synergistic e¡ect elicited by LPS
and IFN-Q on NO synthesis has been demonstrated
to be the result of cooperative interaction between
the IRF-1 and NF-UB sites [14,22].
IFN-Q plays a major role in the activation of mac-
rophages that can act as cytotoxic e¡ector cells, es-
pecially against microorganisms and tumor cells [23].
Activation of macrophages by IFN-Q can cause anti-
viral e¡ects [24], and iNOS induction is involved in
the ability of IFN-Q to inhibit viral replication [25]. It
has been demonstrated by studies on mice that mac-
rophages with a targeted disruption of the IRF-1
gene reveal a de¢ciency in iNOS induction and NO
production [26], and that the iNOS promoter con-
tains an IRF-1 binding site, which is essential for
the induction of iNOS by IFN-Q [22].
Protein kinase C (PKC) has been shown to play an
important role in a wide variety of cellular functions,
such as regulation of receptor interaction with com-
ponents of the signal transduction apparatus, gene
expression and cell proliferation [27^30]. PKCs in
various tissues are polymorphic, and gene structures
of isoenzymes are classi¢ed as conventional (c) and
novel (n) PKC. cPKCs require Ca2 for activation,
whereas nPKCs are independent of Ca2. The N-ter-
minal half of the single chain cPKC contains two
conserved domains: C1, which binds 1,2-diacylglyc-
eride (DAG), phosphatidylserine and phorbol ester,
and C2, which binds Ca2. Although the N-terminal
half of nPKC lacks the C2 domain, thus losing Ca2
dependency for activation, it retains the C1 domain,
enabling it to bind DAG or phorbol esters [28,30^
34]. The roles of PKC activators such as PMA (phor-
bol 12-myristate 13-acetate) for the control of iNOS
induction by IFN-Q have been shown in some cell
types. Although phorbol ester alone failed to pro-
mote NO synthesis, it increased NO synthesis by
IFN-Q due to a prolongation of mRNA stability in
murine peritoneal macrophages [35]. It has been re-
ported that phorbol esters or IFN-Q can induce iNOS
independently; however, IFN-Q blocked the stimula-
tory e¡ect of phorbol ester in rat macrophages and
rat hepatocytes [36,37]. Neither phorbol ester nor
IFN-Q induced NO synthesis in rat smooth muscle
cells, although phorbol ester reduced IFN-Q and
TNF-K-induced iNOS expression by decreasing the
iNOS mRNA [38]. These cellular diversities in iNOS
induction in response to phorbol esters may be due
to multiple mechanisms. Thus, we intended to clarify
the mechanisms of phorbol ester on iNOS induction
in IFN-Q-treated RAW 264.7 cells. In the present
study, we show that the synergistic e¡ect of PMA
on iNOS induction by IFN-Q may depend on eleva-
tion of the transcription rate through IRF-1 activa-
tion in RAW 264.7 cells. The synergistic e¡ect of
PMA on IFN-Q-induced IRF-1 binding activity was
observed in J774 cells as well as RAW 264.7 cells,
but not in peritoneal macrophages.
2. Materials and methods
2.1. Reagents
Recombinant mouse IFN-Q was purchased from
Genzyme (Cambridge, MA). LPS (Escherichia coli
0127: B8, Westphal Type) was purchased from Difco
Laboratories. PMA (phorbol 12-myristate 13-ace-
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tate) was obtained from Oriental Yeast Co. Ro 31-
8220 was purchased from Calbiochem^Novabiochem
Corp. L-[2,3-3H]Arginine (speci¢c activity 40 Ci/
mmol) was obtained from Moravek Biochemicals.
Mouse monoclonal antibody against the 130 kDa
macrophage iNOS was obtained from Funakoshi
Co. All other reagents were purchased from Miyata
Chemical Co., Shimane, and were used without fur-
ther puri¢cation.
2.2. Cell culture
RAW 264.7 cells and J774 cells (murine macro-
phage cell line) were obtained from the Riken Cell
Bank. Cells were grown in Dulbecco’s modi¢ed Ea-
gle’s medium (DMEM) and RPMI 1640, respec-
tively, containing 10% fetal calf serum (FCS), 100
Wg/ml streptomycin, 100 U/ml penicillin G, 2 mM
L-glutamine and 1Unon-essential amino acids at
37‡C under 5% CO2 in humidi¢ed air. Thioglycol-
late-elicited mouse peritoneal macrophages were har-
vested 3 days after intraperitoneal injection of 4 ml
thioglycollate broth (3.5% solution) to 8- to 12-week-
old BALB/C mice, isolated, and were grown in
DMEM as reported previously [35]. Cell viability
was measured by trypan blue uptake. Cell viability
during the treatment with IFN-Q, PMA, Ro 31-8220
or both IFN-Q and PMA was not a¡ected by these
stimulants (cell survival rate: more than 95%).
2.3. Preparation of total cell extracts
RAW 264.7 cells, J774 cells and peritoneal macro-
phages (1.5U106 cells) were treated with IFN-Q,
PMA or both IFN-Q and PMA. After the cells
were washed twice with phosphate-bu¡ered saline
(PBS), 0.25 ml of lysis bu¡er (25 mM Hepes (pH
7.5) containing 10 WM pepstatin, 10 WM leupeptin,
25 mM L-mercaptoethanol and 1% v/v Triton X-100)
was added, and the cells were collected with a dis-
posable rubber scraper and sonicated. The samples
were then centrifuged at 105 000Ug for 20 min at
4‡C, and the supernatants were used for the follow-
ing experiments as total cell extracts.
2.4. Determination of iNOS activity
iNOS activity was determined by measuring the
conversion of [3H]arginine to [3H]citrulline according
to the methods described previously [39,40]. Total
cell extracts were incubated with the reaction mixture
containing 10 mM Hepes bu¡er (pH 7.5), 2 mM
CaCl2, 1 mM NADPH, 10 WM FAD, 10 WM
FMN, 10 WM BH4 and 100 nM [3H]arginine (0.1
WCi) in a total volume of 50 Wl. After incubation at
37‡C for 30 min, the reactions were terminated by
adding 1 ml of 20 mM Hepes (pH 5.5), 2 mM EDTA
and 2 mM EGTA. Reaction mixtures were separated
by a Dowex AG 50WX-8 (Na form, 12U25 mm),
and the products were eluted with 2 ml of water.
[3H]Citrulline was quanti¢ed with a liquid scintilla-
tion counter. The protein concentration was deter-
mined by the method of Bradford using bovine se-
rum albumin as a standard [41].
2.5. Western blotting
RAW 264.7 cells (1.5U106 cells) were treated with
IFN-Q, PMA or both IFN-Q and PMA for 12 h. The
cells were washed twice with PBS, and then solubi-
lized in sodium dodecyl sulfate^polyacrylamide gel
electrophoresis (SDS^PAGE) sample bu¡er, fol-
lowed by dispersion by repeated passage through a
20-gauge needle. The samples (20 Wg protein) were
subjected to 7.5% (w/v) SDS^PAGE, and the gels
were blotted onto nitrocellulose membrane. The
membrane was then immersed for 3 h in PBS con-
taining 0.05% Tween-20 and 0.5% ovalbumin,
washed three times with PBS/0.05% Tween-20 and
incubated overnight at 4‡C with 1 Wg/ml anti-iNOS
antibody. After being washed three times with PBS/
0.05% Tween-20, the membrane was incubated with
HRP-conjugated goat anti-mouse IgG for 90 min.
After washing three times with PBS/0.05% Tween-
20, the immunoblot was developed by the ECL de-
tection system (Amersham Pharmacia Biotech).
2.6. Northern blotting
RAW 264.7 cells (3U106 cells) were treated with
IFN-Q, PMA or both IFN-Q and PMA for 6 h. Total
RNA prepared from cultured RAW 264.7 cells by
AGPC method [42] was electrophoresed in 1.2% aga-
rose^formaldehyde gels and transferred to nylon ¢l-
ters by capillary action in 20USSC. RNA was cross-
linked to the ¢lter by irradiation with UV light. After
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prehybridization, the ¢lters were hybridized with ran-
dom [Q-32P]dCTP (3000 Ci per nmol)-labeled probes
for iNOS. Then the ¢lters were washed, dried and
analyzed by autoradiography. The blots were also
hybridized with a GAPDH cDNA probe. The
gene-speci¢c primers for iNOS (438 bp) or the con-
stitutive glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) cDNA (452 bp) were: 5P-TTCCGAAGT-
TTCTGGCAGCA-3P (sense) and 5P-ATAGGAAA-
AGACT GCACCGAAGAT-3P (antisense), 5P-ACC-
ACAGTCCATGCCATCAC-3P (sense) and 5P-TCC-
ACCACCCTGTTGCTGTA-3P (antisense), respec-
tively.
2.7. Determination of mRNA stability
RAW 264.7 cells were treated with IFN-Q, PMA or
both IFN-Q and PMA for 6 h. Actinomycin D was
added to the cultures (¢nal concentration of 5 Wg/ml)
and the cells were harvested 0, 2, 4, 6 and 8 h after
the addition of actinomycin D. Total RNA was pre-
pared and analyzed by Northern blot hybridization
for iNOS mRNA as described above. Densitometry
of autoradiographs was used to determine and quan-
tify the levels of iNOS mRNA. Estimates of the rel-
ative iNOS mRNA amounts were obtained by divid-
ing the peak densitometry area of iNOS mRNA
band by the area of the GAPDH band.
2.8. Preparation of nuclear extracts
RAW cells, J774 cells and peritoneal macrophages
(3U106 cells) were treated with IFN-Q, PMA or both
IFN-Q and PMA for 2 h. Nuclear proteins were pre-
pared as described previously [43]. Cells were centri-
fuged and washed with Tris^saline (pH 7.9) and then
suspended in 400 Wl of 10 mM Hepes (pH 7.9) con-
taining 10 mM KCl, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT (dithiothreitol) and 0.5 mM
PMSF (phenylmethanesulfonyl £uoride). After being
allowed to swell on ice for 15 min, the cells were
lysed with 0.6% Nonidet P-40, followed by vigorous
vortexing for 10 s. The cell lysates were centrifuged
for 30 s in a microcentrifuge (13 000Ug), and the
resultant pellets were resuspended in 50 Wl of 20
mM Hepes (pH 7.9) containing 0.4 M NaCl, 1 mM
EDTA, 1 mM EGTA, 1 mM DTT and 1 mM
PMSF. The nuclear suspensions were vigorously
shaken at 4‡C for 15 min, followed by centrifugation
in a microcentrifuge (13 000Ug) at 4‡C for 5 min.
The resultant supernatants were stored as nuclear
extracts in small aliquots at 380‡C.
2.9. Electrophoretic mobility shift assay (EMSA)
The IRF-1 (5P-GGA AGC GAA AAT GAA ATT
GAC T-3P)-, NF-UB (5P-AGT TGA GGG GAC TTT
CCC AGG C-3P)-, AP-1 (5P-CGC TTG ATG AGT
CAG CCG GAA-3P)- or CREB (5P-AGA GAT TGC
CTG ACG TCA GAG AGC TAG-3P)-speci¢c dou-
ble-stranded oligonucleotides were labeled with
[Q-32P]ATP by the end-labeling method (Promega
gel shift assay system). Aliquots of nuclear protein
(20^30 Wg) were incubated with these oligonucleo-
tides in 50 mM Tris/HCl bu¡er (pH 7.5) containing
5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT,
250 mM NaCl, 20% glycerol and 0.25 Wg/Wl poly-
(dI-dC) for 20 min at room temperature. Nuclear
proteins complexed with speci¢c double-stranded oli-
gonucleotides for IRF-1, NF-UB, AP-1 or CREB
were analyzed on 7% polyacrylamide gels. After
they were dried, the gels were subjected to auto-
radiography.
3. Results
3.1. E¡ect of PMA on iNOS activity in IFN-Q-treated
RAW 264.7 cells
To investigate whether phorbol esters have a syn-
ergistic e¡ect on the induction of iNOS by IFN-Q,
RAW 264.7 cells (1.5U106 cells/ml) were treated
with 100 U/ml IFN-Q, 10 nM PMA or both 100 U/
ml IFN-Q and 10 nM PMA, respectively, for 12 h,
and then iNOS activity was measured. As shown in
Fig. 1A, IFN-Q treatment increased iNOS activity by
about 2.7-times compared with the control (un-
treated cells: 18.6 þ 1.2 nmol/mg protein per min
vs. IFN-Q : 50.2 þ 2.4 nmol/mg protein per min),
whereas the addition of PMA in the presence of
IFN-Q to the cell cultures apparently increased
iNOS activity by about 2.5-times compared with
that obtained by IFN-Q alone (IFN-Q and PMA:
125.5 þ 3.5 nmol/mg protein per min vs. IFN-Q :
50.2 þ 2.4 nmol/mg protein per min). PMA alone
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failed to increase iNOS activity (data not shown) and
the inability to increase iNOS activity coincided with
the result reported by Maria et al. [44].
To examine the time course of the synergistic e¡ect
of PMA on iNOS induction by IFN-Q, iNOS activ-
ities were measured after RAW 264.7 cells were
treated with PMA in the presence of IFN-Q for 0^
20 h. As shown in Fig. 1B, the addition of 100 U/ml
IFN-Q alone slowly increased iNOS activity up to 20
h, while with simultaneous addition of 100 U/ml
IFN-Q and 10 nM PMA to the cell cultures, the max-
imal iNOS activity was achieved at 12 h and was
about 2.5-times that caused by 100 U/ml IFN-Q
alone. Then iNOS activity slowly decreased through
the following incubation up to 20 h. Ten nM PMA
alone failed to increase iNOS activity during 20 h
(Fig. 1B).
To examine dose-dependent e¡ects of PMA in the
presence of IFN-Q, RAW 264.7 cells (1.5U106 cells/
ml) were treated with increasing concentrations of 0^
500 nM PMA in the presence of 100 U/ml IFN-Q for
12 h. As shown in Fig. 1C, maximal iNOS activity in
the presence of IFN-Q was achieved at 10 nM PMA,
and iNOS activity was gradually decreased when
PMA concentration was over 25 nM PMA.
Next, RAW 264.7 cells (1.5U106 cells/ml) were
treated with increasing concentrations of IFN-Q (1^
400 U/ml) in ¢xed concentration of 10 nM PMA for
12 h. As shown in Fig. 1D, the e¡ect of IFN-Q of
increasing iNOS activity in the presence of 10 nM
PMA was never observed on the treatment with
1 U/ml IFN-Q, but prominent increases were ob-
tained when the IFN-Q concentration was over
10 U/ml. A maximal synergistic e¡ect of IFN-Q was
achieved at 100 U/ml (IFN-Q and PMA: 126.0 þ 1.3
nmol/mg protein per min vs. IFN-Q : 50.2 þ 1.3 nmol/
mg protein per min).
3.2. Participation of PKC in the synergistic e¡ect of
PMA
To examine the involvement of PKC in the syner-
gistic e¡ect of PMA, RAW 264.7 cells (1.5U106 cells/
ml) were treated with 100 U/ml IFN-Q or 100 U/ml
IFN-Q and 10 nM PMA, in the presence of a speci¢c
PKC inhibitor, Ro 31-8220 (1 or 10 WM), for 12 h.
As shown in Table 1, although 10 WM Ro 31-8220 in
the RAW 264.7 cell cultures did not cause signi¢cant
suppression of iNOS activity compared with the con-
trol, the simultaneous addition of 10 WM Ro 31-8220
to IFN-Q or IFN-Q and PMA elicited apparent sup-
pression (by 61.1% and 48.1%, respectively). When
Fig. 1. (A) E¡ect of PMA on iNOS activity in IFN-Q-treated
RAW 264.7 cells. RAW 264.7 cells (1.5U106 cells/ml) were
treated with or without 100 U/ml IFN-Q, 10 nM PMA, or both
100 U/ml IFN-Q and 10 nM PMA for 12 h. (B) Time course of
the synergistic e¡ect of PMA on iNOS activity in IFN-Q-treated
RAW 264.7 cells. The cells (1.5U106 cells/ml) were treated with
100 U/ml IFN-Q (a), 10 nM PMA (E) or 100 U/ml IFN-Q and
10 nM PMA (R) for 0^20 h. (C) Dose-dependent e¡ects of
PMA on iNOS activity in IFN-Q-treated RAW 264.7 cells. The
cells (1.5U106 cells/ml) were treated with increasing concentra-
tions of 0^500 nM PMA in the presence of 100 U/ml IFN-Q for
12 h. (D) Dose-dependent e¡ects of IFN-Q on iNOS activity in
a ¢xed concentration of PMA. RAW 264.7 cells (1.5U106 cells/
ml) were treated with increasing concentrations of 0^400 U/ml
IFN-Q in the presence (E) or absence (a) of 10 nM PMA for
12 h. To determine the iNOS activities, the reaction mixtures
containing 50 Wg protein were assayed at 37‡C for 30 min as
described in Section 2. After the reactions were terminated by
adding 1 ml of 20 mM HEPES (pH 5.5), 2 mM EDTA and
2 mM EGTA, [3H]citrulline was separated by Dowex AG
50WX-8 (Na form, 12U25 mm), which was eluted with 2 ml
of water. [3H]Citrulline was quanti¢ed by liquid scintillation
counter. Results show the mean þ S.E. of three experiments.
BBAMCR 14658 10-10-00
I. Momose et al. / Biochimica et Biophysica Acta 1498 (2000) 19^31 23
RAW 264.7 cells were treated with 1 or 10 WM Ro
31-8220 for 2 h prior to treatment with IFN-Q or
both IFN-Q and PMA, the suppressive e¡ect of Ro
31-8220 was almost the same as that obtained with
simultaneous addition of the stimulants to cell cul-
tures (data not shown). These results indicate that
not only the increase of iNOS activity by IFN-Q,
but also the synergistic e¡ect of PMA may partially
depend on PKC activity.
To further investigate the involvement of PKC ac-
tivity, RAW 264.7 cells (1.5U106 cells/ml) were pre-
treated with 10 nM PMA for 12 h, and after the
medium was replaced by a PMA-free one, the cells
were continuously cultured in the presence of either
100 U/ml IFN-Q or both 100 U/ml IFN-Q and 10 nM
PMA for 12 h. As shown in Fig. 2, when RAW 264.7
cells pretreated with 10 nM PMA were cultured with
IFN-Q and PMA, the iNOS activity decreased to
56.5% compared with that without pretreatment.
Pretreatment of 10 nM PMA slightly decreased
iNOS activity caused by IFN-Q alone and did not
show the synergistic e¡ect. Additionally, pretreat-
ment of 25 nM PMA for 24 h decreased iNOS ac-
tivity by IFN-Q alone to approximately 50% (data
not shown). This results further support the fact
that PKC may be involved in the increase of iNOS
activity by IFN-Q and the synergistic e¡ect of PMA.
3.3. Synergistic e¡ect of PMA on iNOS protein levels
in IFN-Q-treated RAW 264.7 cells
To assess whether the synergistic e¡ect of PMA on
iNOS activity in IFN-Q-treated RAW 264.7 cells is
due to an increase in iNOS protein, immunoblot ex-
periments using a speci¢c monoclonal anti-iNOS
antibody were carried out. RAW 264.7 cells were
treated with each 100 U/ml IFN-Q, 10 nM PMA, or
both 100 U/ml IFN-Q and 10 nM or 100 nM PMA
for 12 h, and cell lysates were subjected to the experi-
ments. As shown in Fig. 3, IFN-Q markedly aug-
mented iNOS protein levels in the density of 130
kD band compared with the control (Fig. 3, lanes
1 and 2), and both 100 U/ml IFN-Q and 10 nM
PMA increased the level by about 2.5-times com-
pared with 100 U/ml IFN-Q alone (Fig. 3, lanes 2
and 4). However, 10 nM PMA alone failed to aug-
ment the iNOS protein level (Fig. 3, lanes 1 and 3).
The simultaneous addition to the culture medium of
10 WM Ro 31-8220 and 100 U/ml IFN-Q or both 100
Table 1
E¡ect of Ro31-8220 for iNOS activity on IFN-Q- or IFN-Q plus PMA-treated RAW 264.7 cells
Treatment iNOS activity (nmol/mg protein per min)
None 100 U/ml IFN-Q 100 U/ml IFN-Q+10 nM PMA
Control 14.8 þ 1.0 45.3 þ 2.6 126.3 þ 6.2
1 WM Ro 31-8220 14.4 þ 0.7 43.9 þ 0.6 111.0 þ 5.9
10 WM Ro 31-8220 13.9 þ 1.4 27.7 þ 0.9 60.7 þ 0.9
Either 100 U/ml IFN-Q or 100 U/ml IFN-Q plus 10 nM PMA-stimulated RAW 264.7 cells (1.5U106 cells/ml) were treated with Ro 31-
8220 (1 or 10 WM) for 12 h. The enzyme preparation and the assay for iNOS activity were carried out as described in Section 2. Re-
sults show the mean þ S.E. of three experiments.
Fig. 2. E¡ect of PMA pretreatment on iNOS activity in IFN-Q-
or both IFN-Q and PMA-treated RAW 264.7 cells. The cells
(1.5U106 cells/ml) were pretreated with (+) or without (3) 10
nM PMA for 12 h, and after the medium was replaced by
PMA-free one, the cells were continuously cultured in the pres-
ence of either 100 U/ml IFN-Q or both 100 U/ml IFN-Q and 10
nM PMA. To determine the iNOS activities, the reaction mix-
tures containing 50 Wg protein were assayed as described in Fig.
1. Results show the mean þ S.E. of three experiments.
*P = 0.0148, IFN-Q with PMA pretreatment (pre-PMA) relative
to IFN-Q without pre-PMA. **P = 0.0003, IFN-Q and PMA
with pre-PMA relative to IFN-Q and PMA without pre-PMA.
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U/ml IFN-Q and 10 nM PMA apparently decreased
iNOS protein levels by about 60% and 48%, respec-
tively, compared with IFN-Q alone or both IFN-Q
and PMA, respectively (Fig. 3, lanes 2 and 6, lanes
4 and 7).
3.4. Synergistic e¡ect of PMA on iNOS mRNA levels
in IFN-Q-treated in RAW 264.7 cells
To assess whether the synergistic e¡ect of PMA on
iNOS protein levels in IFN-Q-treated RAW 264.7
cells is due to increased iNOS mRNA, total RNA
prepared from RAW 264.7 cells treated with 100
U/ml IFN-Q, 10 nM PMA or both 100 U/ml IFN-Q
and 10 nM PMA for 6 h were subjected to Northern
blot analysis. As shown in Fig. 4, IFN-Q apparently
augmented the iNOS mRNA level in the density of
the band that coincides in position with those of
iNOS mRNA compared with the control (Fig. 4,
lanes 1 and 2), and both IFN-Q and PMA increased
iNOS mRNA level by about 3-fold compared with
IFN-Q alone (Fig. 4, lanes 2 and 4). However, PMA
alone failed to increase the iNOS mRNA level (Fig.
4, lanes 1 and 3). The simultaneous addition to the
culture medium of 10 WM Ro 31-8220 to 100 U/ml
IFN-Q or both 100 U/ml IFN-Q and 10 nM PMA
apparently decreased iNOS mRNA levels compared
with IFN-Q or both IFN-Q and PMA, respectively
(Fig. 4, lanes 2 and 5, lanes 4 and 6). LPS, known
as a potent stimulant of iNOS mRNA induction [14],
was used as positive control and augmented iNOS
mRNA to the same level as in the IFN-Q and
PMA-treated cells (Fig. 4, lane 7).
3.5. E¡ect of PMA on iNOS mRNA stability in
IFN-Q-treated RAW 264.7 cells
To investigate whether the synergistic e¡ect of
PMA on iNOS mRNA levels in IFN-Q-treated
RAW 264.7 cells is due to increased iNOS mRNA
stability, 5 Wg/ml actinomycin D was added into the
culture medium after RAW 264.7 cells were treated
with 100 U/ml IFN-Q or both 100 U/ml IFN-Q and 10
nM PMA for 6 h, and then cultured for 0, 2, 4, 6 and
8 h. Total RNA prepared from the cells at each time
were subjected to Northern blot analysis to quantify
iNOS mRNA levels. As shown in Fig. 5, the half-life
of iNOS mRNA from the cells treated with IFN-Q
Fig. 3. Synergistic e¡ect of PMA on iNOS protein levels in
IFN-Q-treated RAW 264.7 cells. The cells (3U106 cells/ml) were
treated with medium alone (lane 1), 100 U/ml IFN-Q (lane 2),
10 nM PMA (lane 3), 100 U/ml IFN-Q and 10 nM PMA (lane
4), 100 U/ml IFN-Q and 100 nM PMA (lane 5), 100 U/ml IFN-
Q and 10 WM Ro 31-8220 (lane 6), 100 U/ml IFN-Q, 10 nM
PMA and 10 WM Ro 31-8220 (lane 7) for 12 h, and then cell
lysates (20 Wg protein) were subjected to 7.5% (w/v) SDS^
PAGE and blotted onto nitrocellulose membrane. The immuno-
blot was developed by the ECL detection system (Amersham
Pharmacia Biotech) as described in Section 2. The data are rep-
resentative of four independent experiments.
Fig. 4. Synergistic e¡ect of PMA on iNOS mRNA levels in
IFN-Q-treated RAW 264.7 cells. The cells (3U106 cells/ml) were
treated with medium alone (lane 1), 100 U/ml IFN-Q (lane 2),
10 nM PMA (lane 3), 100 U/ml IFN-Q and 10 nM PMA (lane
4), 100 U/ml IFN-Q and 10 WM Ro 31-8220 (lane 5), 100 U/ml
IFN-Q, 10 nM PMA and 10 WM Ro 31-8220 (lane 6) and 1 Wg/
ml LPS (lane 7) for 6 h. Total RNA (20 Wg) prepared from
RAW 264.7 cells were separated by agarose gel electrophoresis
and blotted onto nylon ¢lter. The ¢lter was hybridized with ra-
diolabeled iNOS or GAPDH cDNA probe as described in Sec-
tion 2. The data are representative of four independent experi-
ments.
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alone or IFN-Q and PMA was determined to be ap-
proximately 6.7 and 6.5 h, respectively. These results
suggest that PMA did not a¡ect iNOS mRNA stabil-
ity in IFN-Q-treated RAW 264.7 cells.
3.6. E¡ect of PMA on IRF-1 binding activity in
IFN-Q-treated RAW 264.7 cells
To elucidate whether the synergistic e¡ect of PMA
on IFN-Q-induced iNOS mRNA depends on NF-UB,
IRF-1, AP-1 or CREB binding activation, nuclear
extracts from RAW 264.7 cells treated with IFN-Q
or both IFN-Q and PMA were subjected to EMSA
using the speci¢c binding elements for each transcrip-
tion factor. As shown in Fig. 6, 100 U/ml IFN-Q
alone increased the density of the shifted band, which
appeared as a doublet [44] by about 4-times in IRF-1
binding activity compared with the control (Fig. 6
(left), lanes 1 and 2). Although 10 nM PMA alone
did not change the IRF-1 binding activity (Fig. 6
(left), lanes 1 and 3), 5 or 10 nM PMA in the pres-
ence of 100 U/ml IFN-Q caused 1.8 and 2.5-times
increases, respectively, compared with 100 U/ml
IFN-Q alone (Fig. 6 (left), lanes 2, 4 and 5). The
addition of excess unlabeled IRF-E prevented the
band shifts (Fig. 6 (left), lanes 5 and 6), indicating
the speci¢c DNA/protein binding. Furthermore, Ro
31-8220 apparently decreased the IRF-1 binding ac-
tivity in a dose-dependent manner in IFN-Q and
PMA-treated RAW 264.7 cells (Fig. 6 (right), lanes
2^6). Additionally, PMA failed to a¡ect the NF-UB,
AP-1 and CREB binding activity in IFN-Q-treated
RAW 264.7 cells (data not shown). These results in-
dicate that the synergistic e¡ect of PMA on IFN-Q-
Fig. 5. E¡ect of PMA on iNOS mRNA stability in IFN-Q-
treated RAW 264.7 cells. After RAW 264.7 cells (3U106 cells/
ml) were treated with 100 U/ml IFN-Q or both 100 U/ml IFN-Q
and 10 nM PMA for 6 h, 5 Wg/ml actinomycin D was added to
the culture medium and then cultured for 0, 2, 4, 6 and 8 h.
Total RNA (20 Wg) prepared from RAW 264.7 cells were sub-
jected to Northern blotting analysis as described in Fig. 4. Re-
sults show the mean þ S.E. of three experiments.
Fig. 6. E¡ect of PMA on IRF-1 binding activity in IFN-Q-treated RAW 264.7 cells. (Left) RAW 264.7 cells were treated with medium
alone (control, lane 1), 100 U/ml IFN-Q (lane 2), 10 nM PMA (lane 3), 100 U/ml IFN-Q and 5 nM PMA (lane 4), 100 U/ml IFN-Q
and 10 nM PMA (lane 5), 100 U/ml IFN-Q, 10 nM PMA and IRF-1 binding unlabeled DNA (lane 6) for 2 h. (Right) RAW 264.7
cells were treated with 100 U/ml IFN-Q (lane 1), 100 U/ml IFN-Q and 10 nM PMA (lane 2), 100 U/ml IFN-Q, 10 nM PMA and 1, 5,
10, 20 WM Ro 31-8220 (lanes 3^6). Nuclear extracts (20^30 Wg) from the cells were subjected to EMSA using the speci¢c binding ele-
ments for IRF-1 as described in Section 2. The data are representative of four independent experiments.
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induced iNOS mRNA might be exerted through the
IRF-1 activation.
3.7. Comparison of the synergistic e¡ect of PMA on
IRF-1 binding activities in IFN-Q-treated
RAW 264.7 cells, J774 cells and peritoneal
macrophages
We examined by using other macrophage cell line,
J774 cells, and peritoneal macrophages to assess
whether the synergistic e¡ect of PMA on IFN-Q-in-
duced IRF-1 binding activity in RAW 264.7 cells is
cell-speci¢c. After J774 cells and peritoneal macro-
phages were treated with 100 U/ml IFN-Q and/or
10 nM PMA which were the same concentrations
used in the case of RAW 264.7 cells, the cell lysates
and nuclear extracts were subjected to assays of
iNOS and IRF-1 binding activities, respectively.
IFN-Q treatment increased iNOS activity by about
1.6-fold compared with control in J774 cells (IFN-Q
vs. control: 25.3 þ 1.4 nmol/mg protein per min vs.
15.8 þ 1.8 nmol/mg protein per min), and 1.8-fold
compared with control in peritoneal macrophages
(IFN-Q vs. control: 28.8 þ 2.2 nmol/mg protein per
min vs. 16.0 þ 1.0 nmol/mg protein per min). Where-
as the addition of PMA in the presence of IFN-Q
signi¢cantly increased iNOS activity by about 1.8-
fold compared with IFN-Q alone in J774 cells (IFN-
Q and PMA vs. IFN-Q : 45.5 þ 4.0 nmol/mg protein
per min vs. 25.3 þ 1.4 nmol/mg protein per min)
and 1.7-fold compared with IFN-Q alone in perito-
neal macrophages (IFN-Q and PMA vs. IFN-Q :
49.0 þ 4.0 nmol/mg protein per min vs. 28.8 þ 2.2
nmol/mg protein per min), respectively. PMA alone
failed to increase iNOS activity in each cell (data not
shown).
As shown in Fig. 7, IFN-Q alone increased the
IRF-1 binding activity about 1.6- and 1.8-fold com-
pared with the control in J774 cells and peritoneal
macrophages, respectively. PMA alone could not in-
crease the IRF-1 binding activity in each cell. PMA
in the presence of IFN-Q caused 1.5-fold increases
compared with IFN-Q alone in J774 cells. Whereas,
PMA in the presence of IFN-Q could not increase the
IRF-1 binding activity compared with IFN-Q alone in
peritoneal macrophages and the synergistic e¡ect of
PMA was not observed at the concentrations from
1 nM to 200 nM in peritoneal macrophages (data not
shown). Thus, PMA synergistically increased IFN-Q-
induced iNOS activity in RAW 264.7 cells, J774 cells
and peritoneal macrophages, although the synergistic
e¡ect of PMA with IFN-Q on IRF-1 binding activity
was observed in RAW 264.7 cells and J774 cells, but
not in peritoneal macrophages.
4. Discussion
In the present study, PMA synergistically in-
creased iNOS activity, protein and mRNA levels in
IFN-Q-treated RAW 264.7 cells. This e¡ect of PMA
on iNOS mRNA levels in IFN-Q-treated RAW 264.7
cells was due to the elevation of the transcription
rate mediated through IRF-1 without a¡ecting
Fig. 7. E¡ect of PMA on IRF-1 binding activity in IFN-Q-treated RAW 264.7 cells, J774 cells and murine peritoneal macrophages.
RAW 264.7 cells (a) and J774 cells (b) and peritoneal macrophages (c) were treated with medium alone, 100 U/ml IFN-Q, 10 nM
PMA, 100 U/ml IFN-Q and 10 nM PMA for 2 h. Nuclear extracts (20 Wg) from the cells were subjected to EMSA using the speci¢c
binding elements for IRF-1 as described in Section 2. The relative IRF-1 binding activity was evaluated by densitometric analysis.
The intensity of the band in each control experiment is set at 100%.
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iNOS mRNA stability. Ro 31-8220, a PKC inhibitor,
decreased iNOS activity, protein and mRNA levels
and IRF-1 activity, indicating that the e¡ect of PMA
on iNOS induction might occur via the PKC path-
way. We show new evidence that phorbol ester has
synergistic e¡ect on iNOS induction in IFN-Q-treated
RAW 264.7 cells.
The promoter region of the iNOS gene has been
characterized in di¡erent species, including human
and mouse [17,18]. The 1.8-kb murine iNOS pro-
moter region contains consensus sequences for the
binding of transcriptional factors, and some of
them play an important role in control of iNOS ex-
pression [18^21]. The DNA binding proteins that are
involved in the regulation of iNOS expression are
mainly NF-UB and IRF-1 [14,22]. The involvement
of NF-UB activation in the iNOS expression mecha-
nism elicited by proin£ammatory cytokines and LPS
has been widely recognized as an absolute require-
ment, and IFN-Q has proved to be an important
cytokine for iNOS induction, synergistically acting
with LPS and tumor necrosis factor-K or with
phorbol esters in a more exclusive fashion
[14,35,38,45,46]. These e¡ects of IFN-Q on iNOS
transcription have been attributed to the presence
of the sequence for binding IRF-1 in the murine
promoter region of the gene, and this motif acts in
combination with the NF-UB site, giving rise to IFN-
Q-dependent potentiation when macrophages are ac-
tivated with suboptimal doses of LPS [18^21]. Addi-
tionally, the molecular basis for synergistic induction
of iNOS by TNF-K and IFN-Q is mediated through
the NF-UB and IRF-1 in RAW 264.7 cells [47].
Although PMA might modulate iNOS induction as
a cosignal with IFN-Q in RAW 264.7 cells, the syn-
ergistic e¡ect of PMA was mediated through IRF-1,
and not NF-UB. Thus, the action mechanism of
PMA with IFN-Q might be quite di¡erent from that
of LPS or TNF-K, which can induce iNOS through
the activation of NF-UB.
IRF-1 transcriptionally regulates many IFN-in-
ducible genes such as iNOS whose promoter contains
an IRF-1 binding site. In addition, there is another
transcription factor, termed IRF-2, that is structur-
ally similar to IRF-1, but represses the e¡ect of IRF-
1 [48,49]. It has been demonstrated that IFN-K de-
creased the activation of IRF-1 without a¡ecting
NF-UB binding activity and inhibited iNOS expres-
sion by LPS/IFN-Q. This phenomenon could be
based on the decrease in IRF-1 mRNA and the in-
crease in IRF-2 mRNA induced by IFN-K in bovine
retinal pigmented epithelial cells [50]. In the present
study, it is possible that PMA also might a¡ect IFN-
Q-induced IRF-1 expression and/or decreased IRF-2
expression in RAW 264.7 cells. It is also possible that
PMA may directly activate PKC, and in turn in-
crease the binding activity of IRF-1 through phos-
phorylation [51].
We examined the cell speci¢city for the synergistic
e¡ect of PMA with IFN-Q on IRF-1 binding activity
and iNOS in RAW 264.7 cells, J774 cells and peri-
toneal macrophages. PMA had the synergistic e¡ect
on iNOS activity in IFN-Q-treated RAW 264.7 cells,
J774 cells and peritoneal macrophages. The synergis-
tic e¡ect of PMA with IFN-Q on IRF-1 binding ac-
tivity was observed in J774 cells as well as RAW
264.7 cells. The synergistic e¡ect of PMA in J774
cells was less responsive than that in RAW 264.7
cells. This di¡erence of responses between RAW
264.7 cells and J774 cells reminds us of the report,
in which the level of NO synthesis by both LPS and
IFN-Q treatment was di¡erent between RAW264.7
and J774 cells [52]. On the other hand, PMA could
not synergistically increase IFN-Q-induced IRF-1
binding activity in peritoneal macrophages. The re-
sult of the inability of PMA to increase IFN-Q-in-
duced IRF-1 binding activity might support the re-
port that PMA increased NO synthesis by IFN-Q due
to a prolongation of mRNA stability in peritoneal
macrophages [35].
We showed that maximal iNOS activity in the
presence of 100 U/ml IFN-Q was achieved at 10
nM PMA but not at concentrations over 25 nM
PMA. It is worth noting that iNOS activity elicited
by 500 nM PMA in the presence of 100 U/ml IFN-Q
was less than that obtained by 100 U/ml IFN-Q alone
(see Fig. 1C). This phenomenon may be based on the
down-regulation of PKC (proteolytic degradation of
PKC) by phorbol esters. The exposure of various cell
types to phorbol esters has been shown to cause
down-regulation of PKC within a minute to hours
[53,54]. In J774, RAW 264.7 cells and rat smooth
muscle cells, chronic PMA pretreatment resulted in
down-regulation of some isoforms of PKC [55,56]. It
has been also reported that protein kinase C down-
regulation was caused by treatment with high PMA
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concentrations and that phorbol esters activate pro-
tein kinase C maximally in a range of doses [53,54].
The mechanisms of iNOS expression are mainly
regulated at the transcriptional level [18^22], but
there are some reports that post-transcriptional con-
trols, including iNOS mRNA degradation, transla-
tion and iNOS protein degradation, may be involved
in the iNOS expression even when iNOS has already
been induced. Vodovotz et al. demonstrated that
transforming growth factor L1 inhibits IFN-Q-in-
duced iNOS expression in mouse peritoneal macro-
phages at multiple post-transcriptional levels [57].
Gaby et al. reported that the synthetic glucocorticoid
dexamethasone blocked iNOS expression in RAW
264.7 cells at the transcriptional and post-transla-
tional levels [58]. We showed that PMA together
with IFN-Q increased iNOS mRNA without a¡ecting
the iNOS mRNA degradation, suggesting that the
synergistic e¡ect of PMA on IFN-Q-induced iNOS
mRNA production may depend on the elevation of
the transcription rate rather than a prolongation of
mRNA stability. Although it is possible that PMA
synergistically regulates IFN-Q-induced iNOS activity
by promoting translation, inhibition of iNOS protein
degradation or elevation of iNOS activation, we
demonstrated that PMA increased iNOS activity,
protein and mRNA levels and IRF-1 binding activity
by about 2.5- to 3-times, respectively, compared with
IFN-Q alone, indicating that the synergistic e¡ect of
PMA on IFN-Q-induced iNOS may have occurred at
the transcriptional level. Taken together with the
data that iNOS expression is mainly regulated at
the transcriptional level [18^22], we postulated that
the synergistic e¡ect of PMA on IFN-Q-induced
iNOS expression could occur at the transcriptional
level.
The roles of PKC activators such as PMA in the
control of iNOS induction by IFN-Q have been
shown in some cell types. Phorbol ester failed to
promote NO synthesis, whereas IFN-Q induced it,
but phorbol ester increased NO synthesis by IFN-Q
due to a prolongation of mRNA stability in murine
peritoneal macrophages [35]. It has been reported
that phorbol esters or IFN-Q individually induced
iNOS, although IFN-Q blocked the stimulatory e¡ect
of phorbol ester in rat macrophages and rat hepato-
cytes [36,37]. However, in the present study, PMA
did not a¡ect iNOS mRNA stability and failed to
promote iNOS induction in RAW 264.7 cells. These
cellular diversities in iNOS induction in response to
phorbol esters may be due to multiple mechanisms in
various cell types and species. The expression of var-
ious PKC isoforms has been shown to di¡er in the
tissue and cell types, and it was suggested that indi-
vidual PKC isoforms may play cell-type-speci¢c roles
in various cellular responses [59,60]. There are some
reports that PKC isoforms were related to LPS-in-
duced iNOS [61^63]. Furthermore, the synergistic
mechanism of PMA on IFN-Q may be di¡erent
from that of LPS. Thus, it is possible that PMA-
related PKC isoforms may be di¡erent from LPS-
related isoforms in IFN-Q-induced iNOS and that
some PKC isoforms, c or nPKCs, containing the
phorbol ester binding domain are involved in IFN-
Q and PMA-induced iNOS expression. We are now
investigating this question.
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